- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Acumen Pharmaceuticals Inc (ABOS)
Acumen Pharmaceuticals Inc stock price live, this page displays NASDAQ ABOS stock exchange data. View the ABOS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Acumen Pharmaceuticals Inc real time stock price chart below.
What Is the Acumen Pharmaceuticals Inc Stock Price Today?
The Acumen Pharmaceuticals Inc stock price today is 1.360.
What Is the Stock Symbol for Acumen Pharmaceuticals Inc?
The stock symbol for Acumen Pharmaceuticals Inc is ""ABOS.""
What Stock Exchange Does Acumen Pharmaceuticals Inc Trade On?
Acumen Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Acumen Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Acumen Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABOS quote. (ISIN: US00509G2093)
What Is the Acumen Pharmaceuticals Inc Stock Price Today?
The Acumen Pharmaceuticals Inc stock price today is 1.360.
What Is the Stock Symbol for Acumen Pharmaceuticals Inc?
The stock symbol for Acumen Pharmaceuticals Inc is ""ABOS.""
What Stock Exchange Does Acumen Pharmaceuticals Inc Trade On?
Acumen Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Acumen Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Acumen Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABOS quote. (ISIN: US00509G2093)
NASDAQ
Currency in USD
1.360
-0.060(-4.23%)
Closed·
After Hours
1.420+0.060(+4.41%)
·
Fair Value
An estimate of a Acumen Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.360
1.420
52 wk Range
0.855
3.360
ABOS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 3 days
1/2
Fair Value
An estimate of a Acumen Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.3601.420
52 wk Range
0.8553.360
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABOS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Acumen Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
7.800
Upside
+473.53%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 8K Acumen Pharmaceuticals Inc For: 15 July
- Investing.com
- Form 8K Acumen Pharmaceuticals Inc For: 15 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Acumen Pharmaceuticals Inc Company Profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Acumen Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- Acumen reports Q1 2025 net loss of $28.8M, but stock surges 7.14% to $1.078 on Alzheimer's drug progress
- $197.9M cash reserves to support operations into early 2027; R&D expenses increase to $25.3M
- ALTITUDE AD phase two study enrollment completed ahead of schedule; top-line results expected late 2026
- CEO expresses confidence in lead drug candidate sabernatog; company explores subcutaneous administration
- Despite losses, market optimism reflects potential in Alzheimer's treatment development and biomarker research
Last Updated: 13/05/2025, 13:50
Read Full TranscriptCompare ABOS to Peers and Sector
Metrics to compare | ABOS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABOSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −1.6x | −0.5x | |
PEG Ratio | 0.01 | −0.03 | 0.00 | |
Price/Book | 0.5x | 0.7x | 2.6x | |
Price / LTM Sales | - | 66.5x | 3.3x | |
Upside (Analyst Target) | - | 400.6% | 43.5% | |
Fair Value Upside | Unlock | 35.8% | 6.8% | Unlock |
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.800
(+473.53% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.48 / -0.51
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Acumen Pharmaceuticals Trade On?
Acumen Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Acumen Pharmaceuticals?
The stock symbol for Acumen Pharmaceuticals is "ABOS."
What Is the Acumen Pharmaceuticals Market Cap?
As of today, Acumen Pharmaceuticals market cap is 82.38M.
What Is Acumen Pharmaceuticals's Earnings Per Share (TTM)?
The Acumen Pharmaceuticals EPS (TTM) is -1.93.
When Is the Next Acumen Pharmaceuticals Earnings Date?
Acumen Pharmaceuticals will release its next earnings report on 11 Aug 2025.
From a Technical Analysis Perspective, Is ABOS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Acumen Pharmaceuticals Stock Split?
Acumen Pharmaceuticals has split 0 times.
How Many Employees Does Acumen Pharmaceuticals Have?
Acumen Pharmaceuticals has 61 employees.
What is the current trading status of Acumen Pharmaceuticals (ABOS)?
As of 09 Aug 2025, Acumen Pharmaceuticals (ABOS) is trading at a price of 1.36, with a previous close of 1.42. The stock has fluctuated within a day range of 1.36 to 1.42, while its 52-week range spans from 0.86 to 3.36.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.